LY411575

LY411575 is a highly potent, cell-permeable, small-molecule gamma-secretase inhibitor (GSI) originally developed by Eli Lilly. It acts by binding to the gamma-secretase complex, preventing the intramembrane proteolytic cleavage of multiple substrates, including amyloid precursor protein (APP) and Notch receptors. By blocking APP processing, LY411575 significantly reduces the production of neurotoxic amyloid-beta (Aβ40 and Aβ42) peptides, which are implicated in the pathogenesis of Alzheimer's disease. Additionally, its inhibition of Notch signaling suppresses Notch S3 cleavage, which modulates cell differentiation, proliferation, and apoptosis, making it a valuable tool in oncology research for blocking Notch-mediated tumor progression and metastatic seeding. Although highly effective in preclinical models, LY411575 is primarily utilized as a research reagent due to Notch-related toxicities (such as intestinal goblet cell hyperplasia and thymic atrophy) associated with systemic, non-selective gamma-secretase inhibition.